EGFR and cancer: Recent experiments have identified the existence of such populations of “cancer persister cells” in a cell line of EGFR+ nonsmall cell lung cancer (Sharma et al. 2010), indicating that bet-hedging may play a role in the emergence of cancer drug resistance (Ramirez et al. 2016).